Skip to main content
S&P 5007,596.53+0.22%DOW52,248.80+0.92%NASDAQ25,452.52+0.06%BTC$76,886.00-1.27%ETH$2,249.66-0.51%GOLD$3,964.70+1.69%OIL$96.22-7.59%
Smart Investors Daily
SID Premium
AS

NASDAQ · ASND

Ascendis Pharma A/S

Healthcare · Biotechnology

$251.27

Down-$0.51 (-0.20%)

Updated Nov 2, 2026, 6:20 PM

SID Score

6.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
14.33B
P/E ratio
-53.27
Dividend yield
0.00%
52-week range
$203.80 – $282.15
Volume
386.71K
Avg. volume
711.81K

Price performance · ASND

ASND price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ASND closed at $251.27 after 20 trading sessions, up 10.19% for the selected period.

Last close
$251.27
Period change
+10.19%
Period low
$222.69
Period high
$253.00
Daily close
View OHLC price history
ASND OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$253.50$255.61$249.55$251.27386.71K
Oct 29, 2026$250.62$254.20$249.56$253.00491.41K
Oct 28, 2026$246.05$249.88$243.45$249.55660.25K
Oct 27, 2026$243.26$246.58$242.51$245.85599.08K
Oct 26, 2026$243.56$246.40$243.35$245.15545.42K
Oct 23, 2026$242.00$244.58$240.79$243.37575.68K
Oct 22, 2026$239.38$243.87$236.87$242.99539.18K
Oct 21, 2026$236.00$240.21$235.50$238.90662.12K
Oct 20, 2026$230.19$235.875$229.88$234.33394.74K
Oct 19, 2026$227.44$233.19$225.81$229.951.27M
Oct 16, 2026$226.62$226.76$223.7775$225.25680.33K
Oct 15, 2026$230.40$234.01$226.06$226.62403.97K
Oct 14, 2026$222.54$227.83$222.00$227.00995.68K
Oct 13, 2026$225.99$228.91$222.21$223.21592.23K
Oct 12, 2026$229.00$229.2275$226.66$227.00667.45K
Oct 9, 2026$225.08$233.96$223.955$229.23815.74K
Oct 8, 2026$227.83$227.98$219.52$222.69924.77K
Oct 7, 2026$224.36$229.00$223.05$228.41820.55K
Oct 6, 2026$229.21$230.91$222.715$226.051.09M
Oct 5, 2026$229.66$230.732$226.84$228.03783.23K

Latest ASND news

The latest Smart Investors Daily articles mentioning ASND.

Stock researchCompany · Overview

ASND research

Overview

Company profile and research snapshot.

Company profile

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$246.67
Implied upside
—
Analysts
—
ASND recent ratings
DateFirmRatingTarget
Oct 26, 2026CitigroupBuy—
Sep 15, 2026Raymond JamesOutperform—
Sep 2, 2026OppenheimerOutperform—
Sep 1, 2026WedbushOutperform—
Sep 1, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D., Professor of Medicine

Yahoo · Oct 20, 2026

RBC Capital names top healthcare stocks as sector upgraded to overweight

Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head of Equity Strategy Lori Calvasina noted that Healthcare historically moves inversely to Technology’s relative performance versus the S&P 500, making it a natural destination when r

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By